The company operates a proprietary platform integrating computational innovation with scalable biohardware to engineer novel therapeutics. Its pipeline includes GB-0895 (anti-TSLP) advancing in Phase 3 for severe asthma, GB-4362 (MMAE neutralizer) with FDA Fast Track designation, and GB-5267 (MUC16 armored CAR T) developed with Roswell Park Comprehensive Cancer Center, with first patient dosing expected in the second half of 2026.
Cyborg Score Rationale
The company has approximately $516.6 million in cash as of March 31, 2026, providing substantial runway. Multiple Phase 3 and early-stage clinical programs span immunology and oncology, though net loss reached $61.7 million in Q1 2026, reflecting typical clinical-stage company burn rates.
Top Insights
Company went public in February 2026 following an increase in operating expenses associated with public company requirements.
The February 2026 IPO was described as the largest biotechnology IPO to date for the year.
Three clinical programs advancing across immunology and oncology, with GB-0895 in Phase 3 trials and two oncology candidates progressing in 2026.
Operating cash burn accelerated to $80.4 million in Q1 2026 versus $53.2 million in Q1 2025, reflecting increased clinical trial activities.
Named Competitors
Genentech/Roche — Biopharmaceutical company with immunology and oncology portfolios